Melanotan II is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
==== Hydrogels ==== Hydrogels have a high water content, with some hydrogels containing up to 90% water. Active drugs and other substances dispersed as colloids or dissolved in water can be easily taken up by hydrogels. Hydrogels are biocompatible. They also swell to a greater volume than organogels when in contact with water and other natural liquids. Hydrogels can be used as drug delivery vehicles, for transdermal application, ophthalmic drug delivery, cancer treatment or for wound dressing. As a type of water based formulation, hydrogels are generally less greasy and are easier to be removed than oil-based formulations like organogels. Examples of hydrogels include [[aluminium hydroxide|aluminum hydroxide]] gels and [[bentonite magma]].
==== Dance/movement therapy ==== Dance and movement therapy, as a form of active imagination, was developed by Jung and Toni Wolff in 1916 and practiced by Tina Keller-Jenny and other analysts. It remained largely unknown until the 1950s when it was rediscovered by Marian Chace and therapist Mary Whitehouse. Whitehouse, after studying with Martha Graham and Mary Wigman, became a dancer and teacher of modern dance, and, along with Swiss dancer Trudi Schoop, is considered one of the founders of dance/movement therapy in the U.S.
The Port of Dover is a cross-channel ferry, cruise terminal, maritime cargo and marina facility situated in Dover, Kent, south-east England. It is the nearest English port to France, at just 34 kilometres (21 mi) away, and is one of the world's busiest maritime passenger ports, with 11.7 million passengers, 2.6 million lorries, 2.2 million cars and motorcycles and 80,000 coaches passing through it in 2017, and with an annual turnover of £58.5 million a year. This compares with the nearby Channel Tunnel, the only fixed link between the island of Great Britain and the European mainland, which now handles an estimated 20 million passengers and 1.6 million trucks per year. The modern port facility features a large artificial harbour constructed behind stone piers and a defensive concrete breakwater. The port is divided into two main sections: the Eastern Docks serve as the main cross-channel ferry terminal, while the Western Docks contain a cruise ship terminal and a yacht marina along with cargo facilities. The Port of Dover has a long history and possesses several listed buildings and structures. The port is owned and operated by the Dover Harbour Board, a statutory corporation formed by royal charter in 1606 by King James I. Most of the board members of the Dover Harbour Board are appointees of the Department for Transport. The port has its own private police force, the Port of Dover Police. The current port traffic volumes and urban population categorise Dover as a Large-Port Town.
Sources: en.wikipedia.org
=== Norwegian === According to Guinness Book of Records (2001), the longest meaningful word used in Norwegian is minoritetsladningsbærerdiffusjonskoeffisientmålingsapparatur (63 letters), meaning devices for measuring coefficients of diffusion of carriers of minority charges. Nouns, and also verbs and adjectives, can be prefixed as qualifiers to other words quite freely, e.g. to make an unlikely, but understandable and grammatically correct, compound word like damplokomotivfyrbøteraspirantluemerkeprodusentdatterkinoavtaletidspunkt, an agreed meeting time for a cinema date with a daughter of a producer of hat badges for trainees aiming to become firemen on steam locomotives.
Osaka International Cancer Institute (大阪国際がんセンター) is located in Otemae, Chūō-ku, Osaka, Japan. It has 500 beds and is run by the Osaka Prefectural government. This hospital specializes in cancer and adult illness.
== External links == What is a WW domain? Ranganathan lecture on statistical coupling analysis (audio included) Protein folding — a step closer? - A summary of the Ranganathan lab's SCA-based design of artificial yet functional WW domains.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.